Chapter 2: Two Readings

The weeks after the Laishan seminar, Maren could hear arguments through half-open doors on her way to the lab. People lingered after meals to sketch diagrams on napkins. A postdoc in Kassar's lab published a preprint on BDNF promoter accessibility that got fifty-seven internal comments in two days, which was a record. Josip started bringing a second thermos of coffee to the analysis lab because Maren kept drinking his.

"You could bring your own," he said.

"I could," Maren agreed, and did not.

The BDNF trend had given the argument numbers, and numbers changed the temperature. Maren heard people citing specific figures in the hallway — not guessing, not hand-waving, arguing about decimal places. She watched a postdoc and a senior researcher disagree over lunch so precisely that they were drawing on the table with their fingers, tracing curves in spilled water.

Davorka's camp wrote a proposal. It was forty-three pages long and it described, in meticulous physiological detail, a pilot community designed around integrated mechanical exertion. Not a gym. Not an exercise program. A settlement where the infrastructure required human physical input to function — water pumps cranked by hand, grain mills on pedal stations. Heating systems that captured the metabolic output of the people they warmed. The energy calculations alone took Maren an hour to verify. They were correct. Tight, but correct.

Kassar's counter-proposal was twenty-one pages. A pharmacological and genetic intervention protocol targeting the twelve most affected epigenetic pathways. Two years of animal model data behind it. It could be implemented within existing infrastructure. It did not require anyone to move.

Maren read both documents on a Saturday, sitting on the flat limestone ledge behind the west annex where she sometimes went to think. The stone was warm through her trousers. A lizard watched her from a crack in the wall. It did not blink. She read Davorka's proposal first, then Kassar's, then Davorka's again. Her pen left smudges on the margins where the limestone dust got into the ink. She drew a small chart on the back of Kassar's proposal comparing the projected outcomes over three generations. Both curves went up.

Davorka's office on the third floor smelled like pine resin and old paper. Stacks of uncut journals on every surface. A bone-handled letter knife on the desk that Maren had learned not to ask about.

"Sit," Davorka said when Maren appeared in her doorway on a Monday morning three weeks after the seminar. She was reviewing something, reading glasses low on her nose, and did not look up.

Maren sat. She shifted left to avoid the splinter on the armrest before she'd consciously registered doing it.

"I read your proposal," Maren said.

"Everybody read my proposal. Kassar's team printed copies to annotate in their weekly meeting. I'm told they used three colors of ink." Davorka looked up. "Which is more attention than most of my work receives, so I'm choosing to be flattered."

"The energy calculations hold."

"I know they hold. I had you in mind when I wrote them. The question isn't whether they hold. The question is whether you think the thing they describe is viable."

"It's viable at small scale," Maren said. "A community of maybe two hundred, in the right climate, with enough technical knowledge to build and maintain the mechanical systems. The energy math works if the population is young and healthy and committed. It stops working if people get old, or sick, or don't want to do it."

"People get old everywhere. What happens when they get old in a society that captures energy from appropriate exertion rather than peak output?"

"Then the system scales to them. You wrote that in section twelve. Resistance-adjustable cranking, rehabilitation exercises routed through capture devices, the output mattering less than the act."

"I wrote it. Do you believe it?"

Maren leaned back in the hard chair. Through Davorka's window she could see the eastern courtyard. Someone had left a bicycle leaning against the oak tree. It had been there for at least a week.

"I believe the math," she said. "I'm less sure about the part where two hundred people agree to crank water pumps every morning for the rest of their lives."

Davorka took off her reading glasses. "People are messier than math. That's also where the interesting things happen." She paused. "You've also read Yael's proposal."

"I have."

"And?"

"The curves both go up."

Davorka set down her pen. "They do. The question is what happens when you extend them."

"Past three generations?"

"Past twelve."

Maren hadn't run projections past three generations. The error bars became absurd.

Somewhere in the building a door closed. Footsteps in the corridor, unhurried, receding.

"That's speculative," Maren said.

"Everything past next Tuesday is speculative. The question is which speculation you trust more: the one that requires an expanding tower of interventions, each one managing something the body used to manage on its own, or the one that works the same way it has for three hundred thousand years."

Maren shifted in the chair, avoiding the splinter.

"I don't trust either projection. The data runs out at three generations and after that it's just stories we tell about what we think bodies will do."

Davorka put her glasses back on and picked up her pen. "You know where to find me when you know what you think."

Tomas proposed the human trials at the next Institute-wide meeting.

The ventilation hummed. Chairs scraped as people settled. No raised voices. Kassar presented the protocol. It was careful work. Twelve subjects, voluntary enrollment, six-month monitoring period, methylation mapping at four checkpoints, full informed consent. The safety profile from the animal models was strong. The institutional review board had given preliminary approval. Everything was in order.

Davorka asked three questions. They were precise, technical questions about off-target methylation effects in tissues adjacent to the BDNF promoter region. Kassar answered them. The answers were honest: the animal models showed some off-target activity, within acceptable ranges, and the monitoring protocol would catch any drift.

"Acceptable to whom?" Davorka said.

"To the review board. To the statistical threshold established in the protocol. To science."

"The review board evaluates six-month outcomes. I'm asking about six-generation outcomes."

"Nobody can evaluate six-generation outcomes. That's the nature of generational research."

"Which is exactly why I'm cautious about interventions whose consequences we can't evaluate on the timescale that matters."

The room murmured.

Maren sat next to Josip. A woman in the third row crossed her arms when Davorka spoke and uncrossed them when Kassar answered.

Josip whispered, "I count forty-six on the intervention side, thirty-one on the conditions side, and sixteen who haven't committed to a facial expression."

"You counted."

"I'm a microbiologist. I count things that are alive."

The trial was approved, fifty-eight to thirty-four, with one abstention. When the count came around to Maren, her hands stayed in her lap. Her face went warm. Josip glanced at her. She looked at her hands.

Tomas didn't mention it at dinner. He made pasta with herbs from the courtyard garden, opened a bottle of wine they'd been saving, and talked about the enrollment timeline. He moved around the kitchen with a looseness she hadn't seen in weeks. The pasta was good. The wine was good. Tomas was good. She scrubbed the same pot twice after dinner and didn't notice until the water ran cold.

She washed the dishes while he read on the couch. The water was warm. The window was open. She could hear the cicadas, fewer now than in September.

The email from Velden arrived on a Thursday, flagged urgent. The toast was in the toaster. Maren read the email.

Velden. Davorka's pilot community in the Julian Alps. Eighty-seven people cranking water pumps for five years. Nobody at the Institute had expected statistically significant results.

The email contained their first five-year health dataset for the children born in the settlement. Fourteen children, aged one to four. The sample was laughably small.

BDNF markers twenty-five percent above controls. Inflammatory profiles she'd never seen in pediatric data. Bone density, cardiovascular, immune, metabolic — all of it pointing in the same direction, so consistently that in a pharmaceutical trial she would have assumed data fabrication.

She checked the methodology. Solid. Error bars large. Nothing proven.

But the direction was unmistakable.

The toast popped. She didn't move. Her tea went cold.

Tomas came in, saw her face, and stopped.

"What," he said.

She turned the screen toward him.

He read it standing up. He was quiet for a long time. Then he said, "Fourteen subjects."

"I know."

"Five years. One community. No blinding. No randomization."

"I know."

"This wouldn't survive peer review."

"Probably not. But the direction is there, Tomas. Twenty-five percent on BDNF. In one generation. Without touching the genome."

He set the screen down. His jaw was tight.

"This doesn't invalidate the trial," he said.

"I didn't say it did."

"But you're thinking it."

"I'm thinking that we now have data going in two directions and I need to figure out what that means."

"It means we have two data points and insufficient information to draw conclusions. You know this. You're a biostatistician."

"I'm a biostatistician looking at numbers that shouldn't be there." She paused. "I'm not drawing conclusions. I'm having a feeling."

"I don't work with feelings."

"That's not true and we both know it."

He poured himself coffee. He did not sit down. The air through the open window raised the hair on her arms.